A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

被引：2
|
作者：
Sochacki, Andrew L. [1 ]
Burger, Jan A. [2 ]
Ludwig, Carrianne [3 ]
Assaily, Wissam [3 ]
Munasinghe, Wijith [3 ]
Pappano, William [3 ]
Greenberg, Edward [3 ]
Will, Christine [3 ]
Thompson, Meghan C. [4 ]
机构：
[1] START Midwest, Grand Rapids, MI USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181671
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies.
    Chong, Elise A.
    Yuda, Junichiro
    Izutsu, Koji
    Fletcher, Luke Benjamin
    Assaily, Wissam
    Sahtout, Mohammad
    Badawi, Mohamed
    Burke, John M.
    Dean, James P.
    Stevenson, Claudina
    Will, Christine
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
    Ansell, Stephen M.
    Hurvitz, Sara A.
    Koenig, Patricia A.
    LaPlant, Betsy R.
    Kabat, Brian F.
    Fernando, Donna
    Habermann, Thomas M.
    Inwards, David J.
    Verma, Meena
    Yamada, Reiko
    Erlichman, Charles
    Lowy, Israel
    Timmerman, John M.
    CLINICAL CANCER RESEARCH, 2009, 15 (20) : 6446 - 6453
  • [43] Patient reported outcomes from a phase 2 study of copanlisib in patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
    Keating, Karen N.
    Niemeyer, Florian
    Garcia-Vargas, Jose E.
    Childs, Barrett H.
    Dreyling, Martin H.
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
    Torka, Pallawi
    Kambhampati, Swetha
    Chen, Lu
    Wang, Xiaoguang
    Chen, Canping
    Vuong, Dan
    Qin, Hanjun
    Muir, Alexandra
    Orand, Kirsten
    Borja, Ivana
    Lynne Smith, D.
    Herrera, Alex F.
    Spurgeon, Stephen E. F.
    Park, Byung
    Lewis, Lionel D.
    Hernandez-Ilizaliturri, Francisco
    Xia, Zheng
    Danilov, Alexey V.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [45] Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Gaidano, Gianluca
    Goy, Andre
    Provencio, Mariano
    Nagy, Zsolt
    Robak, Tadeusz
    Maddocks, Kami J.
    Buske, Christian
    Korolkiewicz, Roman Pawel
    Striebel, Frank
    Blum, Kristie
    BLOOD, 2015, 126 (23)
  • [46] A Phase 2 Study of Weekly Temsirolimus and Bortezomib for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Wisconsin Oncology Network Study
    Fenske, Timothy S.
    Shah, Namrata M.
    Kim, Kyung Mann
    Saha, Sandeep
    Zhang, Chong
    Baim, Arielle E.
    Farnen, John P.
    Onitilo, Adedayo A.
    Blank, Jules H.
    Ahuja, Harish
    Wassenaar, Tim
    Qamar, Rubina
    Mansky, Patrick
    Traynor, Anne M.
    Mattison, Ryan J.
    Kahl, Brad S.
    CANCER, 2015, 121 (19) : 3465 - 3471
  • [47] Phase 1 clinical study ofAtacicept in patients with relapsed and refractory B-cell lymphoma.
    Ansell, Stephen
    Witzig, Thomas E.
    Novak, Anne
    Inwards, David James
    Porrata, Luis
    Ythier, A.
    Ferrande, L.
    Nestorov, I.
    DeVries, T.
    Sievers, Eric
    BLOOD, 2006, 108 (11) : 770A - 770A
  • [48] Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
    Ansell, SM
    Witzig, TE
    Kurtin, PJ
    Sloan, JA
    Jelinek, DF
    Howell, KG
    Markovic, SN
    Habermann, TM
    Klee, GG
    Atherton, PJ
    Erlichman, C
    BLOOD, 2002, 99 (01) : 67 - 74
  • [49] Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Dere, Randall C. C.
    Beardsley, Richard L. L.
    Lu, Dan
    Lu, Tong
    Ku, Grace H-W.
    Man, Gabriel
    Nguyen, Van
    Kaur, Surinder
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [50] Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
    Yan, Zixun
    Wang, Wen
    Zheng, Zhong
    Hao, Ming
    Yang, Su
    Li, James
    Cheng, Shu
    Wang, Li
    Zhao, Wei-li
    BLOOD, 2018, 132
12345